Edition:
United States

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Global Market

8.51USD
20 Apr 2018
Change (% chg)

$0.26 (+3.15%)
Prev Close
$8.25
Open
$8.24
Day's High
$8.75
Day's Low
$8.22
Volume
2,648
Avg. Vol
4,639
52-wk High
$106.25
52-wk Low
$7.90

Chart for

About

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based... (more)

Overall

Beta: 2.33
Market Cap(Mil.): $13.08
Shares Outstanding(Mil.): 1.52
Dividend: --
Yield (%): --

Financials

  NVIV.OQ Industry Sector
P/E (TTM): -- 33.33 33.60
EPS (TTM): -20.30 -- --
ROI: -130.88 9.89 13.19
ROE: -136.95 14.70 15.00

BRIEF-Invivo Therapeutics Announces Reverse Stock Split

* ANTICIPATES REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 5:00 P.M. EASTERN TIME ON APRIL 16, 2018

Apr 09 2018

BRIEF-Invivo Therapeutics Receives FDA Approval For Controlled Trial Of The Neuro-Spinal Scaffold™

* INVIVO THERAPEUTICS RECEIVES FDA APPROVAL FOR PIVOTAL, RANDOMIZED, CONTROLLED TRIAL OF THE NEURO-SPINAL SCAFFOLD™ IN PATIENTS WITH ACUTE SPINAL CORD INJURY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 08 2018

BRIEF-InVivo Therapeutics Appoints Richard Toselli As Chief Executive Officer

* INVIVO THERAPEUTICS ANNOUNCES APPOINTMENT OF RICHARD TOSELLI, M.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Feb 05 2018

BRIEF-Invivo Therapeutics Says There Is Substantial Doubt About Ability To Continue As A Going Concern

* INVIVO THERAPEUTICS SAYS "THERE IS SUBSTANTIAL DOUBT ABOUT OUR ABILITY TO CONTINUE AS A GOING CONCERN" - SEC FILING

Jan 29 2018

BRIEF-Invivo Therapeutics Announces Purchase Agreement For Up To $15 Mln With Lincoln Park Capital

* INVIVO THERAPEUTICS ANNOUNCES PURCHASE AGREEMENT FOR UP TO $15 MILLION WITH LINCOLN PARK CAPITAL

Jan 26 2018

BRIEF-InVivo Therapeutics Announces Latest Results From INSPIRE

* INVIVO THERAPEUTICS ANNOUNCES LATEST RESULTS FROM INSPIRE AND PROVIDES UPDATE ON PROPOSED CLINICAL PATH FORWARD

Jan 03 2018

InVivo to open crop input unit to outside investors

PARIS, Dec 19 French agricultural group InVivo said on Tuesday that it plans to raise 50 million euros ($59 million) for its Bioline division, which develops crop inputs such as seeds and pesticides, by bringing in outside investors.

Dec 19 2017

BRIEF-InVivo Therapeutics Announces Executive Management And Board Changes

* INVIVO THERAPEUTICS ANNOUNCES EXECUTIVE MANAGEMENT AND BOARD CHANGES

Dec 18 2017

Deals of the day-Mergers and acquisitions

Nov 10 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:

Nov 10 2017

French agricultural group InVivo to buy garden retailer Jardiland

PARIS French agricultural group InVivo has agreed to buy gardening chain Jardiland to strengthen its position in a sector drawing competitors from do-it-yourself stores to internet distributors.

Nov 10 2017

Earnings vs. Estimates